Clinical Trial Results:
Assessment of Active Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa) plasma kinetics in Patients at acute stage of Ischemic Stroke: Prospective, Multicentre, Open, Non-randomised, Biomarker Study
Summary
|
|
EudraCT number |
2017-002760-41 |
Trial protocol |
ES |
Global end of trial date |
05 Apr 2018
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
13 Apr 2019
|
First version publication date |
13 Apr 2019
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
CL2-RTCCAR-001
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Institut de Recherches Internationales Servier (I.R.I.S)
|
||
Sponsor organisation address |
50 rue Carnot, Suresnes Cedex, France, 92284
|
||
Public contact |
Dr Benoît Tyl, Center for Therapeutic Innovation (CTI), Institut de Recherches Internationales Servier , +33 155724366, clinicaltrials@servier.com
|
||
Scientific contact |
Dr Benoît Tyl, Center for Therapeutic Innovation (CTI), Institut de Recherches Internationales Servier, +33 155724366, clinicaltrials@servier.com
|
||
Sponsor organisation name |
Laboratorios Servier S.L
|
||
Sponsor organisation address |
Avenida de los Madroños, 33, Madrid, Spain,
|
||
Public contact |
Mrs Itziar Fernandez Gonzalez, Dpto. de Investigacion y Desarrollo, , Laboratorios Servier S.L, +34 917489014, itziar.fernadezgonzalez@servier.com
|
||
Scientific contact |
Mrs Itziar Fernandez Gonzalez, Dpto. de Investigacion y Desarrollo, , Laboratorios Servier S.L, +34 917489014, itziar.fernandezgonzalez@servier.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
05 Apr 2018
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
05 Apr 2018
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
05 Apr 2018
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary exploratory objective of this trial was to assess the systemic plasma kinetics of the active Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa) during the acute stage of ischemic stroke in patients eligible for recombinant tissue Plasminogen Activator (rtPA) thrombolysis alone or rtPA thrombolysis followed by endovascular thrombectomy (EVT).
|
||
Protection of trial subjects |
This study was conducted in accordance with Good Clinical Practice standards, ethical principles stated in the Declaration of Helsinki and applicable regulatory requirements. After the subject has ended his/her participation in the trial, the investigator provided appropriate medication and/or arrange access to appropriate care for the patient.
|
||
Background therapy |
No Investigational Medicinal Product (IMP) was provided to the patients. The patients received the standard-of-care treatment, including rtPA thrombolysis or rtPA thrombolysis and endovasular thrombectomy if indicated according to current clinical guidelines. | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
15 Nov 2017
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Spain: 35
|
||
Country: Number of subjects enrolled |
France: 2
|
||
Worldwide total number of subjects |
37
|
||
EEA total number of subjects |
37
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
7
|
||
From 65 to 84 years |
17
|
||
85 years and over |
13
|
|
||||||||||||||||
Recruitment
|
||||||||||||||||
Recruitment details |
- | |||||||||||||||
Pre-assignment
|
||||||||||||||||
Screening details |
Patients ≥ 18 years old within 4.5 hours after ischemic stroke symptoms onset, with imaging evidence of cerebral artery occlusion in anterior circulation, and eligible for pharmacological thrombolysis alone or followed by EVT according to current clinical guidelines. | |||||||||||||||
Period 1
|
||||||||||||||||
Period 1 title |
overall trial (overall period)
|
|||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||
Allocation method |
Not applicable
|
|||||||||||||||
Blinding used |
Not blinded | |||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
Group A (rtPA) | |||||||||||||||
Arm description |
No IMP is used in this study. Adult patients at acute stage of ischemic stroke eligible for rtPA (i.e. thrombolysis) alone according to current clinical guidelines and investigator, and having documented cerebral artery occlusion in anterior circulation. | |||||||||||||||
Arm type |
rtPA alone | |||||||||||||||
Investigational medicinal product name |
rtPA as background treatment
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Powder for solution for infusion
|
|||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||
Dosage and administration details |
The recommended dose of alteplase was 0.9 mg/kg over 60 minutes as indicated in the approved SmPC
|
|||||||||||||||
Arm title
|
group B (rtPA+EVT) | |||||||||||||||
Arm description |
No IMP is used in this study. Adult patients at acute stage of ischemic stroke eligible for rtPA + EVT (i.e. thrombolysis + endovascular thrombectomy) according to current clinical guidelines and investigator, and having documented cerebral artery occlusion in anterior circulation. | |||||||||||||||
Arm type |
rtPA + Endovascular thrombectomy | |||||||||||||||
Investigational medicinal product name |
rtPA as background treatment
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Powder for solution for injection
|
|||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||
Dosage and administration details |
The recommended dose of alteplase was 0.9 mg/kg over 60 minutes as indicated in the approved SmPC
|
|||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group A (rtPA)
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
No IMP is used in this study. Adult patients at acute stage of ischemic stroke eligible for rtPA (i.e. thrombolysis) alone according to current clinical guidelines and investigator, and having documented cerebral artery occlusion in anterior circulation. | ||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
group B (rtPA+EVT)
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
No IMP is used in this study. Adult patients at acute stage of ischemic stroke eligible for rtPA + EVT (i.e. thrombolysis + endovascular thrombectomy) according to current clinical guidelines and investigator, and having documented cerebral artery occlusion in anterior circulation. | ||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
|||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Included Set (IS)
|
||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | ||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
All enrolled patients included in the study
|
||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Biomarker Set (BMKS)
|
||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Sub-group analysis | ||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
All enrolled patients included in the study with a rtPA full dose administered
|
||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Group A (rtPA)
|
||
Reporting group description |
No IMP is used in this study. Adult patients at acute stage of ischemic stroke eligible for rtPA (i.e. thrombolysis) alone according to current clinical guidelines and investigator, and having documented cerebral artery occlusion in anterior circulation. | ||
Reporting group title |
group B (rtPA+EVT)
|
||
Reporting group description |
No IMP is used in this study. Adult patients at acute stage of ischemic stroke eligible for rtPA + EVT (i.e. thrombolysis + endovascular thrombectomy) according to current clinical guidelines and investigator, and having documented cerebral artery occlusion in anterior circulation. | ||
Subject analysis set title |
Included Set (IS)
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
All enrolled patients included in the study
|
||
Subject analysis set title |
Biomarker Set (BMKS)
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
All enrolled patients included in the study with a rtPA full dose administered
|
|
|||||||||||||
End point title |
systemic TAFIa plasma level assessment [1] | ||||||||||||
End point description |
The primary endpoint was the systemic TAFIa plasma level
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Groups A and B : intravenous blood samples at baseline and at intervals over 24h since rtPA thrombolysis start
Group B only : one arterial blood sample through the EVT catheter immediately before first pass.
|
||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Within group comparisons versus baseline were specified but were not relevant due to the small sample size and the large inter-individual variability in TAFIa activity. A between group comparison on the change between baseline and T1h was specified in the statistical analysis plan but was not relevant for the same reasons. |
|||||||||||||
|
|||||||||||||
Notes [2] - it was not possible to interpret inferential statistics due to a few number of biomarkers data [3] - It was not possible to interpret inferential statistics due to a few number of biomarkers data |
|||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
-from the signature of the informed consent up to the participant’s last study visit for all adverse events.
-irrespective of the time of onset after the end of the study in case of serious adverse events related to the research.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
20
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group rtPA
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Adult patients at acute stage of ischemic stroke eligible for rtPA (i.e. thrombolysis) alone according to current clinical guidelines, and having documented cerebral artery occlusion in anterior circulation. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group rtPA + EVT
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Adult patients at acute stage of ischemic stroke eligible for rtPA + EVT (i.e. thrombolysis + endovascular thrombectomy) according to current clinical guidelines, and having documented cerebral artery occlusion in anterior circulation. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |